サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1795370

幹細胞臍帯血の世界市場

Stem Cell Umbilical Cord Blood

出版日
ページ情報
英文 127 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.25円
幹細胞臍帯血の世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 127 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

幹細胞臍帯血の世界市場は2030年までに77億米ドルに到達

2024年に26億米ドルと推定される幹細胞臍帯血の世界市場は、2024年から2030年にかけてCAGR 19.9%で成長し、2030年には77億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである医薬品エンドユーズは、CAGR 21.5％を記録し、分析期間終了時には42億米ドルに達すると予測されます。研究機関エンドユーズ分野の成長率は、分析期間中CAGR17.2％と推定されます。

米国市場は6億8,350万米ドルと推定、中国はCAGR18.7％で成長予測

米国の幹細胞臍帯血市場は、2024年に6億8,350万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに12億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは18.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ18.5％と17.1％と予測されています。欧州では、ドイツがCAGR約14.4%で成長すると予測されています。

世界の幹細胞臍帯血市場- 主要動向と促進要因のまとめ

臍帯血幹細胞への関心を高めるものは何か？

造血前駆細胞や間葉系前駆細胞を豊富に含む臍帯血幹細胞は、重要な再生医療ツールとして台頭してきました。その用途は、血液疾患、免疫不全、一部の代謝性疾患の治療に及ぶ。出生時に臍帯血を採取してバンクに保管することは、家族にとって積極的なヘルスケアの選択肢となっており、自家または同種移植の可能性を提供しています。臨床医は、臍帯血は拒絶反応率が低く、非侵襲的で胚性幹細胞に関する論争を避けることができるため、倫理的に容易であるとしています。公的な臍帯血バンクや民間の臍帯血保管サービスは、産科センターと協力して、収集プロトコルを簡素化しています。さらに、臍帯血は、神経学、自己免疫疾患、組織修復などの新たな治療法のための幹細胞源として研究されており、従来の血液学の枠を超えた拡大パイプラインを示しています。

臍帯血の採取と保存は、技術的な進歩によって向上しているのでしょうか？

DMSOフリーの凍結保護剤、自動制御された凍結速度、最適化された保存システムなど、先進的な凍結保存ソリューションは、融解後の細胞の生存率を高めています。ハイスループット・プロセシング・プラットフォームは、標準化された減容、赤血球除去、CD34+濃縮を可能にしています。デジタル追跡は、採取キットから保管庫まで、エンド・ツー・エンドのサンプルトレーサビリティを保証し、バンクが規制監査や認定基準に準拠することを支援します。電子カルテとの統合により、医師は可用性、適合基準、組織適合性レポートを迅速に確認することができ、移植前の意思決定が容易になり、転帰が改善されます。

なぜ家族やクリニックは臍帯血バンクを受け入れているのか？

小児の慢性疾患や遺伝性疾患の増加により、予防的な安全装置として臍帯血バンクへの関心が高まっています。両親は、バンクに保管された臍帯血を、自分の子供や近親者にとって価値の高い生物学的資産と見なしています。官民パートナーシップによるバンキング・モデルの進歩により、経済的に余裕のない家族も、調査アクセスが可能な公的バンキングを支援できるようになり、公平性が促進されています。臨床医や移植センターは、細胞数が多く、抗原適合が最適な臍帯血ユニットを優先します。供給業者が支援活動や教育プログラムを拡大するにつれて、バンクされた臍帯血の治療可能性に対する認識が高まっています。

臍帯血幹細胞市場の成長の原動力は？

幹細胞臍帯血市場の成長は、高度な低温技術、治療使用事例の拡大、ヘルスケア政策の進化に関連するいくつかの要因によって牽引されています。FDAが承認した20以上の治療法と、神経、自己免疫、代謝の適応症に対する臨床試験の増加が需要を拡大しています。強化された凍結保存技術は長期的な生存性と有効性を確保し、患者の転帰を向上させる。欧州、アジア太平洋、北米などの地域では、政府の奨励策や保険適用政策がバンキング導入を後押ししています。分娩センター、バンク、研究機関の間のパートナーシップは、収集物流を合理化しています。最後に、臍帯血の治療価値に対する社会的認知の高まりと、認定バンクに対するブランドの信頼が、民間および公的保管の両方に拍車をかけています。

セグメント

エンドユーザー（医薬品エンドユーザー、調査エンドユーザー、病院エンドユーザー、バイオバンクエンドユーザー）

調査対象企業の例

  • AlphaCord LLC
  • Americord Registry
  • ATCC（American Type Culture Collection）
  • Celularity
  • Cells4Life Group LLP
  • CellResearch Corporation
  • Cord Blood Registry（CBR）
  • Cord Blood Registry（ViaCord, PerkinElmer）
  • CordforLife
  • Cordlife Group Ltd
  • Cryo-Cell International
  • FamiCord Group
  • Global Cord Blood Corporation
  • LifeCell International
  • MiracleCord
  • NECBB（New England Cord Blood Bank）
  • PerkinElmer（ViaCord）
  • Precision Cellular Storage/Virgin Health Bank
  • Relicord
  • StemCyte

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP38110

Global Stem Cell Umbilical Cord Blood Market to Reach US$7.7 Billion by 2030

The global market for Stem Cell Umbilical Cord Blood estimated at US$2.6 Billion in the year 2024, is expected to reach US$7.7 Billion by 2030, growing at a CAGR of 19.9% over the analysis period 2024-2030. Pharmaceuticals End-Use, one of the segments analyzed in the report, is expected to record a 21.5% CAGR and reach US$4.2 Billion by the end of the analysis period. Growth in the Research Institutes End-Use segment is estimated at 17.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$683.5 Million While China is Forecast to Grow at 18.7% CAGR

The Stem Cell Umbilical Cord Blood market in the U.S. is estimated at US$683.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 18.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.5% and 17.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.4% CAGR.

Global Stem Cell Umbilical Cord Blood Market - Key Trends & Drivers Summarized

What’s Driving Interest in Umbilical Cord Blood Stem Cells?

Umbilical cord blood stem cells, rich in hematopoietic and mesenchymal progenitors, have emerged as vital regenerative medicine tools. Their applications span treatments for blood disorders, immune deficiencies, and some metabolic diseases. Collecting and banking cord blood at birth has become a proactive healthcare choice for families, offering a potential autologous or allogeneic transplant source. Clinicians rely on the cells’ lower rejection rates and ethical ease-as collection is non-invasive and avoids embryonic stem cell controversies. Public cord blood banks and private storage services are collaborating with obstetric centers to simplify collection protocols. Additionally, cord blood is being explored as a stem cell source for emerging therapies in neurology, autoimmune disorders, and tissue repair, indicating an expansion pipeline beyond traditional hematology.

Are Technological Improvements Enhancing Collection and Storage?

Advanced cryopreservation solutions- using DMSO-free cryoprotectants, automated controlled-rate freezing, and optimized storage systems-are increasing cell viability post-thaw. High-throughput processing platforms are enabling standardized volume reduction, red blood cell depletion, and CD34+ enrichment. Digital tracking ensures end-to-end sample traceability-from collection kit to storage vault-helping banks comply with regulatory audits and accreditation standards. Integration with electronic health records allows physicians to quickly verify availability, matching criteria, and histocompatibility reports-facilitating pre-transplant decision-making and improving outcomes.

Why Are Families and Clinics Embracing Cord Blood Banking?

The rise in chronic and genetic pediatric disorders has elevated interest in cord blood banking as a preventative safeguard. Parents view banked cord blood as a high-value biological asset for their child and immediate family. Advances in public-private partnership banking models allow families without means to support research-accessible public banking, promoting equity. Clinicians and transplant centers prioritize cord blood units with high cell counts and optimal antigen matching. As suppliers expand outreach and educational programs, awareness around banked cord blood’s therapeutic potential is increasing.

What’s Powering the Growth in the Cord Blood Stem Cell Market?

The growth in the stem cell umbilical cord blood market is driven by several factors related to advanced cryogenic technology, expanded therapeutic use cases, and evolving healthcare policies. Over two dozen FDA-approved therapies and increasing clinical trials for neurological, autoimmune, and metabolic indications are broadening demand. Enhanced cryopreservation techniques ensure long-term viability and efficacy, enhancing patient outcomes. Government incentives and insurance coverage policies in regions like Europe, Asia-Pacific, and North America are supporting banking adoption. Partnerships between birthing centers, banks, and research institutions are streamlining collection logistics. Finally, growing public awareness of cord blood’s therapeutic value and branding trust in accredited banks are fueling both private and public storage.

SCOPE OF STUDY:

The report analyzes the Stem Cell Umbilical Cord Blood market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

End-Use (Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use, Biobanks End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 37 Featured) -

  • AlphaCord LLC
  • Americord Registry
  • ATCC (American Type Culture Collection)
  • Celularity
  • Cells4Life Group LLP
  • CellResearch Corporation
  • Cord Blood Registry (CBR)
  • Cord Blood Registry (ViaCord, PerkinElmer)
  • CordforLife
  • Cordlife Group Ltd
  • Cryo-Cell International
  • FamiCord Group
  • Global Cord Blood Corporation
  • LifeCell International
  • MiracleCord
  • NECBB (New England Cord Blood Bank)
  • PerkinElmer (ViaCord)
  • Precision Cellular Storage / Virgin Health Bank
  • Relicord
  • StemCyte

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Stem Cell Umbilical Cord Blood - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Blood-Related Disorders Drives Adoption of Cord Blood Stem Cell Therapies
    • Increased Use in Transplant Procedures Strengthens Clinical Relevance of Banked Cord Blood
    • Government Support and Public Banking Initiatives Expand Access and Awareness
    • Technological Advancements in Cryopreservation Improve Cell Viability and Storage Duration
    • Expansion of Private Cord Blood Banks Boosts Consumer Participation and Industry Funding
    • Regenerative Medicine Developments Propel Use of Cord Blood in Non-Hematologic Applications
    • Standardization of Regulatory Frameworks Enhances Global Market Credibility
    • Surge in Stem Cell Clinical Trials Broadens Therapeutic Indications and Market Potential
    • Awareness Campaigns and Obstetrician Recommendations Increase Collection Rates
    • Strategic Collaborations With Hospitals Facilitate On-Site Collection Services
    • Increased Investments in Stem Cell Research Strengthen Commercial Viability
    • Innovation in Cell Expansion and Differentiation Techniques Enhances Utility of Stored Cells
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Stem Cell Umbilical Cord Blood Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Stem Cell Umbilical Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Stem Cell Umbilical Cord Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pharmaceuticals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pharmaceuticals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Pharmaceuticals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Biobanks End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Biobanks End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Biobanks End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: China 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Stem Cell Umbilical Cord Blood by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Stem Cell Umbilical Cord Blood by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: France 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Stem Cell Umbilical Cord Blood Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • TABLE 53: Rest of World Recent Past, Current & Future Analysis for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Rest of World Historic Review for Stem Cell Umbilical Cord Blood by End-Use - Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Rest of World 16-Year Perspective for Stem Cell Umbilical Cord Blood by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use and Biobanks End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION